Probi Logo

Probi

Develops and manufactures clinically proven probiotics for B2B supplement & nutrition partners.

PROB | ST

Overview

Corporate Details

ISIN(s):
SE0001280355
LEI:
5493004CJOCT273MU397
Country:
Sweden
Address:
Ideongatan 1A, 223 70 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Probi is an international biotechnology company that specializes in the research, development, and manufacturing of clinically documented probiotics and biotic solutions. The company operates on a B2B model, providing partners in the dietary supplement and nutrition industries with end-to-end services, from strain development to finished, private-label products. Probi's portfolio is segmented into specific health areas, including digestive, immune, metabolic, mental, and women's health, as well as solutions tailored for healthy aging and children. The firm emphasizes science-backed innovation and clinically proven efficacy for its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-03 09:20
Delisting Announcement
Avnotering av Probi
Swedish 99.1 KB
2025-02-03 09:20
Delisting Announcement
Delisting of Probi
English 103.2 KB
2025-01-22 15:55
Major Shareholding Notification
Swedish 9.1 KB
2025-01-21 09:47
Major Shareholding Notification
Swedish 8.9 KB
2025-01-20 22:01
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Probi AB (publ)
English 123.5 KB
2025-01-20 22:01
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Probi AB (publ)
Swedish 82.2 KB
2025-01-20 22:00
Delisting Announcement
Probi applies for delisting and convenes an Extraordinary General Meeting
English 109.7 KB
2025-01-20 22:00
Delisting Announcement
Probi ansöker om avnotering och kallar till extra bolagsstämma
Swedish 104.6 KB
2025-01-09 08:00
Report Publication Announcement
Probi senarelägger bokslutskommuniké för 2024
Swedish 92.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi postpones year-end report 2024
English 81.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi senarelägger bokslutskommuniké för 2024
Swedish 92.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi postpones year-end report 2024
English 81.1 KB
2024-12-13 17:18
M&A Activity
Statement from the independent bid committee of Probi in relation to the public…
English 142.9 KB
2024-12-13 17:17
M&A Activity
Uttalande från den oberoende budkommittén i Probi med anledning av Symrise offe…
Swedish 140.4 KB
2024-11-20 07:20
M&A Activity
Probi’s Board comments on Symrise’s public takeover offer
English 101.9 KB

Automate Your Workflow. Get a real-time feed of all Probi filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Probi

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Probi via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-30 Jean-Yves Parisot Other Buy 142,586 49,905,100.00 SEK
2024-11-22 Jean-Yves Parisot Other Buy 42,076 14,726,600.00 SEK
2024-11-21 Jean-Yves Parisot Other Buy 77,405 27,091,750.00 SEK
2024-11-20 Jean-Yves Parisot Other Buy 169,053 59,168,550.00 SEK
2022-05-06 Henrik Lundkvist Other Buy 100 27,981.00 SEK
2022-04-29 Tom Rönnlund Other Buy 400 122,296.00 SEK
2022-04-28 Tom Rönnlund Other Buy 955 287,015.70 SEK
2020-05-06 Tom Rönnlund Other Buy 400 100,000.00 SEK

Peer Companies

OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
OssDsign AB Logo
Develops and markets nanosynthetic bone graft putty for spinal fusion surgery.
Sweden
OSSD
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX

Talk to a Data Expert

Have a question? We'll get back to you promptly.